We are analyzing https://link.springer.com/article/10.1007/s11102-007-0025-y.

Title:
Utility of Free IGF-I Measurements | Pituitary
Description:
For nearly 30 years, the endogenous bioactivity of insulin-like growth factor I (IGF-I) has been estimated by its circulating concentrations of immunoreactive IGF-I, obtained after either removal or inactivation of the IGF-binding proteins (IGFBPs), and today serum/plasma total IGF-I serves as a useful parameter in the diagnosis and clinical control of growth hormone (GH) disorders. Different assays for the measurement of free, unbound IGF-I were introduced more than a decade ago. Nevertheless, this measurement remains controversial, and in daily clinical practice serum total IGF-I has retained its position as the most widely used IGF-related measurement in GH disorders. This review will provide a survey of data on free versus total IGF-I, with particular reference to GH disorders. As it will be clear, there is reasonable clinical evidence to conclude that both in the diagnosis of as well as during treatment of patients with GH disorders, serum/plasma total IGF-I should remain the primary IGF-related measurement. However, in certain patients the inclusion of free IGF-I may be useful and therefore, some guidelines for the inclusion of free IGF-I measurements will be given.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Social Networks

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

growth, article, google, scholar, cas, pubmed, insulinlike, free, igfi, hormone, endocrinol, factor, clin, frystyk, serum, metab, total, patients, ørskov, proteins, binding, protein, horm, res, igf, deficiency, diagnosis, factors, rev, measurement, van, endocr, juul, factori, clinical, disorders, skjærbæk, human, igfbp, children, privacy, cookies, content, research, pituitary, igfbinding, subjects, suppl, obesity, levels,

Topics {✒️}

population-based case-control study month download article/chapter chronic renal failure growth hormone-binding protein intramuscular microsphere-encapsulated octreotide short-term caloric restriction article pituitary aims growth factor-binding protein-1 growth factor-binding protein-2 primary igf-related measurement growth hormone-deficient patients acid-labile subunit growth factor-binding proteins growth hormone-deficient adults igf-binding protein-3 concentrations full article pdf serum/plasma total igf van wyk jj privacy choices/manage cookies igf-binding protein-3 igf-related measurement growth hormone secretion growth hormone release growth hormone replacement liu jl kinase receptor activation chen jw growth hormone deficiency growth-hormone deficiency related subjects serum growth hormone accurate alternative short-term administration igf-binding proteins igf binding proteins-1 article frystyk european economic area balint peric la low-dose rhgh conditions privacy policy igfbps-1-3 protease activity reasonable clinical evidence somatostatin analogue som230 specific negative determinants de herder ww igfbp-3 protease activity van doorn growth factors–measurements article log accepting optional cookies

Questions {❓}

Bang P, Ahlsen M, Berg U, Carlsson-Skwirut C (2001) Free insulin-like growth factor I: are we hunting a ghost?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Utility of Free IGF-I Measurements
         description:For nearly 30 years, the endogenous bioactivity of insulin-like growth factor I (IGF-I) has been estimated by its circulating concentrations of immunoreactive IGF-I, obtained after either removal or inactivation of the IGF-binding proteins (IGFBPs), and today serum/plasma total IGF-I serves as a useful parameter in the diagnosis and clinical control of growth hormone (GH) disorders. Different assays for the measurement of free, unbound IGF-I were introduced more than a decade ago. Nevertheless, this measurement remains controversial, and in daily clinical practice serum total IGF-I has retained its position as the most widely used IGF-related measurement in GH disorders. This review will provide a survey of data on free versus total IGF-I, with particular reference to GH disorders. As it will be clear, there is reasonable clinical evidence to conclude that both in the diagnosis of as well as during treatment of patients with GH disorders, serum/plasma total IGF-I should remain the primary IGF-related measurement. However, in certain patients the inclusion of free IGF-I may be useful and therefore, some guidelines for the inclusion of free IGF-I measurements will be given.
         datePublished:2007-04-11T00:00:00Z
         dateModified:2007-04-11T00:00:00Z
         pageStart:181
         pageEnd:187
         sameAs:https://doi.org/10.1007/s11102-007-0025-y
         keywords:
            Free IGF-I
            Total IGF-I
            IGF-I bioactivity
            GH disorders
            Obesity
            Chronic renal failure
            Endocrinology
            Human Physiology
         image:
         isPartOf:
            name:Pituitary
            issn:
               1573-7403
               1386-341X
            volumeNumber:10
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Kluwer Academic Publishers-Plenum Publishers
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Jan Frystyk
               affiliation:
                     name:Aarhus University Hospital
                     address:
                        name:Medical Research Laboratories, Clinical Institute and Medical Department M (Diabetes and Endocrinology), Aarhus University Hospital, Aarhus C, Denmark
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Utility of Free IGF-I Measurements
      description:For nearly 30 years, the endogenous bioactivity of insulin-like growth factor I (IGF-I) has been estimated by its circulating concentrations of immunoreactive IGF-I, obtained after either removal or inactivation of the IGF-binding proteins (IGFBPs), and today serum/plasma total IGF-I serves as a useful parameter in the diagnosis and clinical control of growth hormone (GH) disorders. Different assays for the measurement of free, unbound IGF-I were introduced more than a decade ago. Nevertheless, this measurement remains controversial, and in daily clinical practice serum total IGF-I has retained its position as the most widely used IGF-related measurement in GH disorders. This review will provide a survey of data on free versus total IGF-I, with particular reference to GH disorders. As it will be clear, there is reasonable clinical evidence to conclude that both in the diagnosis of as well as during treatment of patients with GH disorders, serum/plasma total IGF-I should remain the primary IGF-related measurement. However, in certain patients the inclusion of free IGF-I may be useful and therefore, some guidelines for the inclusion of free IGF-I measurements will be given.
      datePublished:2007-04-11T00:00:00Z
      dateModified:2007-04-11T00:00:00Z
      pageStart:181
      pageEnd:187
      sameAs:https://doi.org/10.1007/s11102-007-0025-y
      keywords:
         Free IGF-I
         Total IGF-I
         IGF-I bioactivity
         GH disorders
         Obesity
         Chronic renal failure
         Endocrinology
         Human Physiology
      image:
      isPartOf:
         name:Pituitary
         issn:
            1573-7403
            1386-341X
         volumeNumber:10
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Kluwer Academic Publishers-Plenum Publishers
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Jan Frystyk
            affiliation:
                  name:Aarhus University Hospital
                  address:
                     name:Medical Research Laboratories, Clinical Institute and Medical Department M (Diabetes and Endocrinology), Aarhus University Hospital, Aarhus C, Denmark
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Pituitary
      issn:
         1573-7403
         1386-341X
      volumeNumber:10
Organization:
      name:Kluwer Academic Publishers-Plenum Publishers
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Aarhus University Hospital
      address:
         name:Medical Research Laboratories, Clinical Institute and Medical Department M (Diabetes and Endocrinology), Aarhus University Hospital, Aarhus C, Denmark
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Jan Frystyk
      affiliation:
            name:Aarhus University Hospital
            address:
               name:Medical Research Laboratories, Clinical Institute and Medical Department M (Diabetes and Endocrinology), Aarhus University Hospital, Aarhus C, Denmark
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Medical Research Laboratories, Clinical Institute and Medical Department M (Diabetes and Endocrinology), Aarhus University Hospital, Aarhus C, Denmark
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(182)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.96s.

LINK . SPRINGER . COM {}